LUNGevity Foundation· @LUNGevity · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
@danieltanmd
@nccsingapore
discusses why KRAS G12D is NOT just "the next G12C" & why zoldonrasib matters #AACR26. KRAS G12D is biologically distinct from G12C:
More common in people without tobacco exp
Lower TMB & PD-L1 expression
Less "immunogenic", fewer CD8+ T cells
Heat 26 · 15 likes · 0 replies · 11 reposts
Source: LUNGevity Foundation · x.com